The clinical effect of antiangiogenesis targeted therapy in advanced colorectal cancer patients with K-ras mutation

XIA Xue-ming; MAO Zhi-yuan; SU Dan; WANG Li-jie; BAI Li

Abstract：Objective: To investigate the efficacy and safety of bevacizumab (BEV) combined with chemotherapy in advanced colorectal cancer patients with K-ras mutation.Methods: Sixty patients diagnosed as advanced colorectal cancer with pathology confirmed K-ras mutation from January 2008 to January 2014 in our hospital were analyzed retrospectively. All patients were received the treatment of bevacizumab combined with different chemotherapy. The efficacy was evaluated according to RECIST standards. Time to progression (TTP) and adverse effects were also observed.Results:Among the 60 patients, the objective response rate (ORR) was 23.3%, the disease control rate (DCR) was 85.0%; the ORRs for the first and second line targeted therapy were 30.3% and 16.0%, respectively. The DCRs for the first and second line targeted therapy were 87.9% and 84.0%, respectively. The ORR and DCR of 12 patients was 8.3% and 75.0% respectively, who continuously received BEV and switched chemotherapy after disease progression. The ORR was higher in patients treated with FOLFIRI plus BEV while comparing with that of patients treated with FOLFOX plus BEV (27.6% vs 20.0%), however, there was no significant difference; nosignificant difference was observed in DCR either (89.7% vs 86.7%). Disease progression was observed in 37 patients and the TTP ranged from 1.4 to 13.4 months. The median TTP was 5.4 months (95%CI 3.9–6.8 months). Conclusion:Bevacizumab combined chemotherapy, especially used as first line , showed good efficiency and was well tolerated in advanced colorectal cancer patients with K-ras mutation.